Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity

• Lena Winstedt,

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯
• Sofia Järnum,

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯
• Emma Andersson Nordahl,

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯
• Andreas Olsson,

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯
• Anna Runström,

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯
• Robert Bockermann,

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯
• Christofer Karlsson,

  Affiliation Department of Clinical Sciences, Lund, Lund University, SE-221 84 Lund, Sweden

  ⨯
• Johan Malmström,

  Affiliation Department of Clinical Sciences, Lund, Lund University, SE-221 84 Lund, Sweden

  ⨯
• Gabriella Samuelsson Palmgren,

  Affiliation Clinical Trials Unit, Skåne University Hospital, Lund, Sweden

  ⨯
• Ulf Malmqvist,

  Affiliation Clinical Trials Unit, Skåne University Hospital, Lund, Sweden

  ⨯
• Lars Björck ,

  * E-mail: christian.kjellman@hansamedical.com (CK); lars.bjorck@med.lu.se (LB)

  Affiliation Department of Clinical Sciences, Lund, Lund University, SE-221 84 Lund, Sweden

  ⨯
• Christian Kjellman

  * E-mail: christian.kjellman@hansamedical.com (CK); lars.bjorck@med.lu.se (LB)

  Affiliation Hansa Medical AB, Scheelevägen 22, P.O. Box 785, SE-22007 Lund, Sweden

  ⨯